188 related articles for article (PubMed ID: 17698234)
1. Circumventing the heterogeneity and instability of human serum albumin-interferon-alpha2b fusion protein by altering its orientation.
Zhao HL; Xue C; Wang Y; Li XY; Xiong XH; Yao XQ; Liu ZM
J Biotechnol; 2007 Sep; 131(3):245-52. PubMed ID: 17698234
[TBL] [Abstract][Full Text] [Related]
2. Increasing the homogeneity, stability and activity of human serum albumin and interferon-alpha2b fusion protein by linker engineering.
Zhao HL; Yao XQ; Xue C; Wang Y; Xiong XH; Liu ZM
Protein Expr Purif; 2008 Sep; 61(1):73-7. PubMed ID: 18541441
[TBL] [Abstract][Full Text] [Related]
3. Disruption of Pichia pastoris PMR1 gene decreases its folding capacity on human serum albumin and interferon-alpha2b fusion protein.
Zhao HL; Xue C; Wang Y; Duan QF; Xiong XH; Yao XQ; Liu ZM
Yeast; 2008 Apr; 25(4):279-86. PubMed ID: 18350526
[TBL] [Abstract][Full Text] [Related]
4. Elimination of the free sulfhydryl group in the human serum albumin (HSA) moiety of human interferon-alpha2b and HSA fusion protein increases its stability against mechanical and thermal stresses.
Zhao HL; Xue C; Wang Y; Sun B; Yao XQ; Liu ZM
Eur J Pharm Biopharm; 2009 Jun; 72(2):405-11. PubMed ID: 19462475
[TBL] [Abstract][Full Text] [Related]
5. Preparation and biological evaluation of a glycosylated fusion interferon directed to hepatic receptors.
Cai G; Jiang M; Zhang B; Zhou Y; Zhang L; Lei J; Gu X; Cao G; Jin J; Zhang R
Biol Pharm Bull; 2009 Mar; 32(3):440-3. PubMed ID: 19252292
[TBL] [Abstract][Full Text] [Related]
6. Balancing the pharmacokinetics and pharmacodynamics of interferon-α2b and human serum albumin fusion protein by proteolytic or reductive cleavage increases its in vivo therapeutic efficacy.
Zhao HL; Xue C; Du JL; Ren M; Xia S; Liu ZM
Mol Pharm; 2012 Mar; 9(3):664-70. PubMed ID: 22224503
[TBL] [Abstract][Full Text] [Related]
7. Construction and characterization of a potent, long-lasting recombinant human serum albumin-interferon α1 fusion protein expressed in Pichia pastoris.
Tian S; Li Q; Yao W; Xu C
Protein Expr Purif; 2013 Aug; 90(2):124-8. PubMed ID: 23748141
[TBL] [Abstract][Full Text] [Related]
8. Drug evaluation: Albuferon-alpha--an antiviral interferon-alpha/albumin fusion protein.
Chemmanur AT; Wu GY
Curr Opin Investig Drugs; 2006 Aug; 7(8):750-8. PubMed ID: 16955687
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of a potent, long-lasting recombinant human serum albumin-interferon-alpha2b fusion protein expressed in Pichia pastoris.
Huang YS; Chen Z; Yang ZY; Wang TY; Zhou L; Wu JB; Zhou LF
Eur J Pharm Biopharm; 2007 Sep; 67(2):301-8. PubMed ID: 17418549
[TBL] [Abstract][Full Text] [Related]
10. Development and biological activity of long-acting recombinant human interferon-α2b.
Zhang Q; Wang C; Ma F; Yao L; Gao H; Zhu L; Zheng L
BMC Biotechnol; 2020 Mar; 20(1):16. PubMed ID: 32169063
[TBL] [Abstract][Full Text] [Related]
11. An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.
Sung C; Nardelli B; LaFleur DW; Blatter E; Corcoran M; Olsen HS; Birse CE; Pickeral OK; Zhang J; Shah D; Moody G; Gentz S; Beebe L; Moore PA
J Interferon Cytokine Res; 2003 Jan; 23(1):25-36. PubMed ID: 12639296
[TBL] [Abstract][Full Text] [Related]
12. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon.
Walker A; Dunlevy G; Rycroft D; Topley P; Holt LJ; Herbert T; Davies M; Cook F; Holmes S; Jespers L; Herring C
Protein Eng Des Sel; 2010 Apr; 23(4):271-8. PubMed ID: 20093262
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a single amino acid substitution at position 79 of human IFN-α2b in interferon-receptor assembly and activity.
Talebi S; Saeedinia A; Zeinoddini M; Ahmadpour F; Sadeghizadeh M
Prep Biochem Biotechnol; 2019; 49(8):735-743. PubMed ID: 31135267
[TBL] [Abstract][Full Text] [Related]
14. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative.
Ramon J; Saez V; Baez R; Aldana R; Hardy E
Pharm Res; 2005 Aug; 22(8):1374-86. PubMed ID: 16078148
[TBL] [Abstract][Full Text] [Related]
15. A new method to produce monoPEGylated dimeric cytokines shown with human interferon-α2b.
Chang CH; Rossi EA; Cardillo TM; Nordstrom DL; McBride WJ; Goldenberg DM
Bioconjug Chem; 2009 Oct; 20(10):1899-907. PubMed ID: 19736932
[TBL] [Abstract][Full Text] [Related]
16. [Expression in Pichia pastoris and properties of human serum albumin-interferon alpha2b chimera].
Chang SH; Gong X; Yang ZY; Wang TY; Ma GC; Ma QJ; Wu J
Sheng Wu Gong Cheng Xue Bao; 2006 Mar; 22(2):173-9. PubMed ID: 16607939
[TBL] [Abstract][Full Text] [Related]
17. Long-term stabilization of a new freeze-dried and albumin-free formulation of recombinant human interferon alpha 2b.
Ruiz L; Reyes N; Sotolongo J; Aroche K; Aldana R; Báez R; Hardy E
PDA J Pharm Sci Technol; 2006; 60(1):72-8. PubMed ID: 17089680
[TBL] [Abstract][Full Text] [Related]
18. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
Grace M; Youngster S; Gitlin G; Sydor W; Xie L; Westreich L; Jacobs S; Brassard D; Bausch J; Bordens R
J Interferon Cytokine Res; 2001 Dec; 21(12):1103-15. PubMed ID: 11798469
[TBL] [Abstract][Full Text] [Related]
19. Production of potent long-lasting consensus interferon using albumin fusion technology in Pichia pastoris expression system.
Naseem MU; Ahmed N; Khan MA; Tahir S; Zafar AU
Protein Expr Purif; 2020 Feb; 166():105509. PubMed ID: 31604114
[TBL] [Abstract][Full Text] [Related]
20. Pegylation of IFN-alpha and antiviral activity.
Boulestin A; Kamar N; Sandres-Sauné K; Alric L; Vinel JP; Rostaing L; Izopet J
J Interferon Cytokine Res; 2006 Dec; 26(12):849-53. PubMed ID: 17238827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
